Jazz Pharmaceuticals (JAZZ) Research & Development (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Research & Development of $196.0 million for Q1 2026, up 8.47% year-over-year from $180.7 million in Q1 2025, and down 8.37% quarter-over-quarter from $213.9 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Research & Development (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $196.0 million for Q1 2026.
- In Q1 2026, Research & Development rose 8.47% year-over-year to $196.0 million; the TTM figure through Mar 2026 stood at $798.1 million (down 5.2% YoY), while the FY2025 annual figure was $782.7 million, down 11.46% from the prior year.
- Research & Development for Q1 2026 stood at $196.0 million, down from $213.9 million in the prior quarter.
- The five-year high for Research & Development was $240.5 million in Q4 2024, with the low at $130.0 million in Q1 2022.
- The 5-year median for Research & Development is $198.2 million (2025), against an average of $194.3 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 69.75% in 2022, then fell 18.91% in 2025.
- Jazz Pharmaceuticals' Research & Development stood at $172.6 million in 2022, then climbed by 25.53% to $216.6 million in 2023, then gained by 11.03% to $240.5 million in 2024, then declined by 11.06% to $213.9 million in 2025, then declined by 8.37% to $196.0 million in 2026.
- Business Quant data shows JAZZ's Research & Development at $196.0 million in Q1 2026, $213.9 million in Q4 2025, and $198.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 207.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 207.50 Mn |
| Mar 31, 2026 | 196.00 Mn |
| Dec 31, 2025 | 213.91 Mn |
| Sep 30, 2025 | 198.20 Mn |
| Jun 30, 2025 | 189.97 Mn |
| Mar 31, 2025 | 180.70 Mn |
| Dec 31, 2024 | 240.50 Mn |
| Sep 30, 2024 | 199.92 Mn |
| Jun 30, 2024 | 220.73 Mn |
| Mar 31, 2024 | 222.85 Mn |
| Dec 31, 2023 | 216.61 Mn |
| Sep 30, 2023 | 234.40 Mn |
| Jun 30, 2023 | 209.24 Mn |
| Mar 31, 2023 | 189.41 Mn |
| Dec 31, 2022 | 172.56 Mn |
| Sep 30, 2022 | 148.87 Mn |
| Jun 30, 2022 | 139.05 Mn |
| Mar 31, 2022 | 129.98 Mn |
| Dec 31, 2021 | 155.44 Mn |
| Sep 30, 2021 | 141.04 Mn |